Inve US ▾
EVEVH

Evolent Health (EVH) Q2 FY26 earnings call: guidance and Q&A

Earnings call· Jun 2026 (Q2 FY26)· Health Care· Aug 6, 2026

Source: earnings call transcript

Executive summary

Evolent Health Q2 FY26 — Strong Performance Suite Growth and Raised Full-Year Guidance

Evolent Health delivered strong Q2 FY26 results, driven by significant Performance Suite growth and successful launches with Highmark and Aetna. The company raised its full-year revenue and adjusted EBITDA guidance, while also announcing a major new oncology partnership and demonstrating meaningful scale with its AI-powered Auth Intelligence platform. Despite anticipated headwinds from Medicaid and exchange membership attrition in 2027, management expressed confidence in delivering strong adjusted EBITDA growth through operational efficiencies and continued Performance Suite expansion.

Highlights

6

  • Total revenue of $653 million, up 31% versus Q1.

  • Adjusted EBITDA of $28 million, up 27% versus Q1.

  • Full-year revenue guidance raised to $2.6 billion to $2.7 billion.

  • Midpoint of adjusted EBITDA guidance raised to $120 million to $135 million.

  • New oncology Performance Suite partnership expected to generate $300 million in annualized revenue.

  • Auth Intelligence platform improved auto approval rates by up to 20 percentage points.

Concerns

4

  • Q2 2026 medical expense ratio (MER) was 95%, up from 93% in Q1, reflecting Highmark launch and higher reserves.

  • Operating cash flow was approximately $10 million cash used in operating activities in Q2, impacted by $20 million repayment of pass-through PBM proceeds.

  • Expected membership declines in Medicaid (approximately 20% decline of Medicaid expansion members) and exchange populations in 2027.

  • Specialty Tech and Services revenue decreased 3% sequentially due to code review scope changes.

Guidance & targets

CategoryTargetConfidence
Full Year 2026 Revenue
$2.6 billion to $2.7 billion
high materiality
High
Full Year 2026 Adjusted EBITDA
$120 million to $135 million
high materiality
High
Full Year 2026 Medical Expense Ratio (MER)
approximately 93%
medium materiality
High
Q2 to Q3 Adjusted EBITDA Increase
approximately $4 million to $7 million
medium materiality
High
Q3 to Q4 Adjusted EBITDA Increase
$7 million to $15 million
medium materiality
High
Full Year 2026 Adjusted Cost of Revenue (ex-medical claims) + Adjusted SG&A
approximately $675 million
medium materiality
High
Full Year 2026 Cash Flow from Operations
$10 million to $20 million
medium materiality
High
Full Year 2026 Software Development and Capital Expenditures
$25 million to $30 million
medium materiality
High
Full Year 2027 Revenue Growth
more than 25%
high materiality
High
Full Year 2027 Adjusted EBITDA Midpoint
at or above $150 million
high materiality
High
Medicaid Expansion Members Decline
probably a 20% decline
medium materiality
Medium

Product announcements

ProductTypeDetails
Auth Intelligence platformupdate

Deals & partnerships

Existing advanced imaging client Oncology Performance Suite partnership approximately $300 million annualized revenue

Partnership will cover approximately 1.5 million lives across Medicaid and Medicare populations spread through 11 states. Includes full enhanced contractual protections.

Current regional Blue Cross plan and former NIA customer Broaden use of Evolent specialty technology and services platform by adding new products and extending existing products to additional populations. less than $5 million annualized revenue

Proves out cross-sell opportunity across customer base. Includes MSK and cardio products.

Risks & headwinds

Higher Medical Expense Ratio (MER) due to new launches Q2 FY26, expected to be higher in Q3 FY26

95% in Q2, up from 93% in Q1

Mitigation:Expected to improve meaningfully into Q4 as clinical programs take effect and favorable contractual true-ups flow through.

Lower operating cash flow due to one-time items Q2 FY26, majority of items expected to move beyond in 2027

approximately $10 million cash used in operating activities in Q2, impacted by $20 million pass-through PBM proceeds repayment

Mitigation:Expect cash flow performance to improve in 2027.

Medicaid membership declines 2027

approximately 20% decline of Medicaid expansion members, translating to 4% to 5% membership impact for Evolent

Mitigation:Strong Performance Suite growth and small market share allow growth past these headwinds; T&S next year will probably be flat to down a bit.

Exchange membership attrition and client-specific market exits 2027

expected membership attrition

Mitigation:Strong Performance Suite growth and small market share allow growth past these headwinds; management is staying close to clients and believes the industry rationalization is far along.

Year 1 investments for new Performance Suite growth and AI investments 2027

earnings drag from signing additional Performance Suite contracts

Mitigation:Underpinned by improved Performance Suite care margins, significant cost reduction and productivity initiatives, and proven performance of Auth Intelligence platform.

What to watch in Q3 FY26

Highmark claims performance visibility

next few months
Current Positive early indicators, clinical engagement rates trending above targets, provider engagement exceeded expectations.
Target Greater visibility into claims performance.

Why it matters

Highmark is a significant partnership, and claims performance is a key indicator of its financial impact and success.

We expect to have greater visibility into claims performance over the next few months, but we're incredibly happy with our progress so far.

Find out whether EVH delivers this. Inve re-checks your case every morning.

Q&A highlights

How is the reserving process for new contracts holding up, and are there any discernible changes in utilization, especially for Part B drugs in oncology?

Mario Ramos stated that reserving is in line with industry trends, showing comfortable optimism. On utilization, Evolent sees nothing different from the broader industry, with trends modulating where acuity hasn't changed. However, client-specific market changes and membership mix create noise, making direct comparisons difficult.

“I would say we're probably in line with everything that I've seen in the industry where we're definitely -- if I look at favorable prior period development as a way to think through whether we're over under reserving. We've all -- industry came out of a period of very tough utilization numbers and expenses, and I think we're all kind of rebounding from that.”

asked by Kevin Caliendo · answered by Mario Ramos

2 min read 5 chapters

Detailed narrative

Strong Growth and Renewals

Evolent continues to experience a positive sales environment, securing a new oncology Performance Suite partnership covering 1.5 million lives across 11 states, expected to launch by December 2026 and generate $300 million in annualized revenue. Additionally, a regional Blue Cross plan expanded its use of Evolent's specialty technology and services platform, demonstrating cross-sell opportunities. The company also successfully renewed three of its largest customers in 2026, providing significant visibility into the 2027 outlook.

Successful Performance Suite Launches

The launches with Highmark (May 1, 2026) and Aetna (earlier this year) have shown strong early indicators. Clinical engagement rates are trending above targets, and provider engagement has exceeded initial expectations for Highmark. Aetna also shows strong clinical engagement and claims-based performance in line with expectations, supporting the overall strength of the business given the scale of these partnerships.

AI Platform and Cost Improvement

Evolent's Auth Intelligence platform, built on the 2024 Machinify acquisition, is reaching meaningful scale, with Q2 being a "tipping point." The platform has improved auto approval rates by up to 20 percentage points (e.g., from 55% to 75%) without clinical quality degradation, completing cases in minutes instead of days. Over one-third of authorization volume previously requiring manual clinical review is now evaluated by AI, contributing to long-term margin targets and employee satisfaction.

2027 Outlook and Strategic Priorities

The company expects strong revenue growth of over 25% in 2027, driven by renewing business and new contracts, despite anticipated membership headwinds from Medicaid work requirements and client-specific market exits. Management is committed to delivering meaningful adjusted EBITDA growth, targeting at least $150 million at the midpoint, supported by improved Performance Suite care margins, significant cost reduction initiatives, and accelerated AI investments.

Capital Structure and Debt Refinancing

Evolent is actively pursuing strategies to improve its capital structure and address 2029 maturities within the next 12 to 24 months. This involves a combination of adjusted EBITDA growth, improved cash flow conversion, disciplined capital allocation, and exploring capital markets and strategic options. The goal is to significantly improve leverage ratios and the maturity profile, enhancing financial flexibility for future opportunities.

Summary of the company's earnings call; see how call summaries are prepared. Not investment advice.